Why Appen, Cettire, DroneShield, and Imugene Shares Are Racing Higher
Why Appen, Cettire, DroneShield, and Imugene Shares Are Racing Higher
The Cettire share price is up 21% to $1.27. This morning, analysts at Bell Potter urged investors with a high tolerance for risk to buy this luxury products retailer's shares. According to the note, the broker has retained its speculative buy rating with a $2.00 price target. This still implies potential upside of almost 60% over the next 12 months even after today's gains. It said: "We continue to see plenty of upside in revenue/earnings from 3Q25 onwards considering overall improving demand conditions and benefits in CTT's lean business model, however with a higher near term risk profile priced into the name at current levels. Given the uncertainties ahead as the company resolves audit issues, we rate the stock as Speculative Buy."In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.2% to 8,074.4 points.
在下午交易時，標普/ASX 200指數（ASX：XJO）正朝着本週開盤下跌的方向走。截至撰寫時，基準指數下跌了0.2%，至8074.4點。
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:
以下列出了四隻ASX股票，它們沒有被拖後腿，這就是它們上漲的原因：
The Appen share price is up 5% to $1.05. This is despite there being no news out of the artificial intelligence data services company. However, it is worth noting that Appen's shares were sold off last week. This could mean that some investors believe they have been oversold and a buying opportunity has been created. The Appen share price remains down 20% since this time last week.
Appen的股價上漲了5%，達到了1.05美元。儘管這家人工智能數據服務公司沒有任何新聞，但值得注意的是，Appen的股票上週被拋售了。這可能意味着一些投資者認爲它們被拋售過度，出現了買入機會。Appen的股價自上週以來下跌了20%。
The Cettire share price is up 21% to $1.27. This morning, analysts at Bell Potter urged investors with a high tolerance for risk to buy this luxury products retailer's shares. According to the note, the broker has retained its speculative buy rating with a $2.00 price target. This still implies potential upside of almost 60% over the next 12 months even after today's gains. It said: "We continue to see plenty of upside in revenue/earnings from 3Q25 onwards considering overall improving demand conditions and benefits in CTT's lean business model, however with a higher near term risk profile priced into the name at current levels. Given the uncertainties ahead as the company resolves audit issues, we rate the stock as Speculative Buy."
Cettire的股價上漲了21%，達到了1.27美元。今天早上，貝爾·波特的分析師敦促高風險承受能力的投資者買入這家奢侈品零售商的股票。根據報告，經紀人保留了其預計的買入評級和2.00美元的目標價位。即使在今天的上漲之後，這仍然意味着在未來12個月內有將近60%的上漲空間。報告稱：「考慮到整體需求狀況的改善和CTT精益業務模式的好處，我們認爲從2025年第3季度開始，收入/盈利有很大的上升空間，儘管目前股價已融入較高的近期風險配置。考慮到公司在解決審計問題方面面臨的不確定性，我們將股票評級爲預測性買入。」
The DroneShield share price is up 8% to $1.43. This counter drone technology company's shares have been on fire in recent sessions. This followed the release of a bullish broker note out of Bell Potter last week. It said: "We remain confident the company will deliver a significantly improved 2H performance based on 1) the significant level of inventory on hand to facilitate rapid fulfilment, 2) the historical seasonality of the business with >80% of CY23 revenue recorded in the 2H and 3) numerous near-term sales opportunities, including recently announced military aid packages." However, its price target of $1.35 has now been surpassed.
DroneShield的股價上漲了8%，達到了1.43美元。這家反無人機技術公司的股票在最近幾個交易日表現出色。這是根據上週貝爾·波特發佈的一份看好報告。報告稱：「我們對該公司在下半年的業績有很大信心，原因如下，首先，公司手頭存貨的數量非常大，可以快速交付；其次，業務在下半年的復季節性顯著，年營業收入的80%以上是在下半年實現的；第三，有很多近期的銷售機會，包括最近宣佈的軍事援助計劃。」然而，1.35美元的目標價位已經被超過了。
$Imugene Ltd (IMU.AU)$
The Imugene share price is up 11% to 6.9 cents. Investors have been buying this clinical stage immuno-oncology company's shares after it announced promising results from a trial. The 1b clinical trial was testing Imugene's azer-cel (an allogeneic off-the-shelf CD19 CAR T) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). It is a type of non-Hodgkin's lymphoma (NHL).
Imugene的股價上漲11%，達到6.9美分。投資者在該公司宣佈臨床試驗取得有望結果後紛紛購買該公司的股票。這項10億人民幣的臨床試驗是在復發/難治瀰漫性大B細胞淋巴瘤（DLBCL）患者身上測試Imugene的azer-cel（一種異基因離體第19型CAR T細胞）的療效。該病種屬於非霍奇金淋巴瘤（NHL）的一種。
